## Rec'd PCT/PTO 03 MAR 2006 10/544093

## SEQUENCE LISTING

```
<110> Yednock, Ted
      Vasquez, Nicki
      Bard, Frederique
      Seubert, Peter A.
<120> ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA FOR
      PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
<130> 15270J-009820US
<140> US 10/544,093
<141> 2004-01-31
<150> WO PCT/US2004/002856
<151> 2004-01-31
<150> US 60/444,150
<151> 2003-02-01
<160> 27
<170> PatentIn version 3.2
<210> 1
<211>
      42
<212> PRT
<213> Homo sapiens
<400> 1
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
                                   10
               5
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                25
           20
Gly Leu Met Val Gly Gly Val Val Ile Ala
<210> 2
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Reversomer of A-beta 1-5
<400> 2
Arg Phe Glu Ala Asp
                5
<210> 3
<211> 17
<212> PRT
```

```
<213> Artificial
<220>
<223> Artificial peptide derived from residues 323-339 of ovalbumin.
<400> 3
Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly
                                   10
Arg
<210> 4
<211> 16
<212> PRT
<213> Plasmodium sp.
<400> 4
Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
               5
                                   10
<210> 5
<211> 10
<212> PRT
<213> Hepatitis B virus
<400> 5
Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
               5
<210> 6
<211> 19
<212> PRT
<213> Artificial
<220>
<223> Heat Shock Protein 65 fragment
<400> 6
Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
                                   10
Asn Glu Gly
<210> 7
<211> 14
<212> PRT
<213> Artificial
```

<220>

```
<223> Bacille Calmette-Guerin fragment
<400> 7
Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu
<210> 8
<211> 15
<212> PRT
<213> Clostridium tetani
<400> 8
Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
                                  10
               5
<210> 9
<211> 21
<212> PRT
<213> Clostridium tetani
<400> 9
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
                5
Ala Ser His Leu Glu
           20
<210> 10
<211> 16
<212> PRT
<213> Human immunodeficiency virus
<400> 10
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
                                    10
<210> 11
<211> 13
<212> PRT
<213> Artificial
<220>
<223> PADRE peptide
<220>
<221> MISC FEATURE
<222> (3)..(3)
<223> X is cyclohexylalanine, tyrosine, or phenylalanine.
```

<400> 11

```
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
<210> 12
<211> 58
<212> PRT
<213> Artificial
<220>
<223> A-beta fragment-tetanus toxoid fusion protein
<220>
<221> MISC_FEATURE
<222>
      (1)..(43)
<223> Only a contiguous fragment of residues 1-43 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<400> 12
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                25
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala
                            40
Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
                        55
<210> 13
<211> 64
<212> PRT
<213> Artificial
<220>
<223> A-beta fragment-tetanus toxoid fusion protein
<220>
<221> MISC FEATURE
<222>
      (1)..(43)
<223> Only a contiguous fragment of residues 1-43 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<400> 13
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
                5
                                    10
                                                        15
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
```

30

25

20

- Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Phe Asn Asn Phe Thr 35 40 45
- Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 50 55 . 60
- <210> 14
- <211> 58
- <212> PRT
- <213> Artificial
- <220>
- <223> A-beta fragment-tetanus toxoid fusion protein
- <220>
- <221> MISC\_FEATURE
- <222> (1)..(43)
- <223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.
- <400> 14
- Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 10 15
- Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30
- Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala 35 40 45
- Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 50 55
- <210> 15
- <211> 79
- <212> PRT
- <213> Artificial
- <220>
- <223> A-beta fragment tetanus-toxoid fusion protein
- <220>
- <221> MISC FEATURE
- <222> (1)..(43)
- <223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.
- <400> 15
- Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 15

```
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30
```

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala 35 40 45

Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val 50 55 60

Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 65 70 75

<210> 16

<211> 56

<212> PRT

<213> Artificial

<220>

<223> Padre-A-beta fragment fusion protein

<220>

<221> MISC FEATURE

<222> (3)..(3)

<223> X is cyclohexylalanine, tyrosine, or phenylalanine.

<220>

<221> MISC FEATURE

<222> (14)..(56)

<223> Only a contiguous fragment of residues 14-56 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<400> 16

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu 1 5 10 15

Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe 20 25 30

Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met 35 40 45

Val Gly Gly Val Val Ile Ala Thr 50 55

<210> 17

<211> 142

<212> PRT

<213> Artificial

```
<220>
<223> A-beta-A-beta-A-beta-Padre fusion protein
<220>
<221>
      MISC FEATURE
<222>
      (1)..(43)
      Only a contiguous fragment of residues 1-43 are present.
<223>
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221>
      MISC FEATURE
<222>
       (44)..(86)
      Only a contiguous fragment of residues 44-86 are present.
<223>
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221>
      MISC FEATURE
<222>
      (87)..(129)
      Only a contiguous fragment of residues 87-129 are present.
<223>
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221> MISC FEATURE
<222>
      (132)..(132)
<223>
      X is cyclohexylalanine, tyrosine, or phenylalanine.
<400> 17
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                25
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg
His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala
Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly
Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
                85
Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser
            100
                                105
                                                     110
```

125

Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala

120

115

```
Thr Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
<210> 18
<211> 185
<212> PRT
<213> Artificial
<220>
<223>
      Fusion protein
<220>
<221>
      MISC FEATURE
<222>
       (3)..(3)
      X is cyclohexylalanine, tyrosine, or phenylalanine.
<223>
<220>
<221>
      MISC_FEATURE
<222>
      (14)..(56)
<223> Only a contiguous fragment of residues 14-56 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221> MISC_FEATURE
<222>
      (57)..(99)
<223> Only a contiguous fragment of residues 57-99 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221> MISC FEATURE
      (100)..(142)
<222>
<223> Only a contiguous fragment of residues 100-142 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221> MISC FEATURE
<222>
      (143)..(185)
       Only a contiquous fragment of residues 143-185 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<400> 18
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu
                5
                                    10
                                                        15
Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe
                                                     30
            20
Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met
        35
                            40
Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser
    50
                        55
```

Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val

Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val 85 90 95

Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His 100 105 110

His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly 115 120 125

Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Asp Ala 130 135 140

Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val 145 150 155 160

Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu 165 170 175

Met Val Gly Gly Val Val Ile Ala Thr 180 185

<210> 19

<211> 56

<212> PRT

<213> Artificial

<220>

65

<223> Fusion protein

<220>

<221> MISC FEATURE

<222> (1)..(43)

<223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (46)..(46)

<223> X is cyclohexylalanine, tyrosine, or phenylalanine.

<400> 19

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30

```
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Ala Lys Xaa Val Ala
                            40
Ala Trp Thr Leu Lys Ala Ala Ala
    50
<210>
       20
<211>
       60
<212>
      PRT
<213> Artificial
<220>
<223>
      Fusion protein
<220>
<221> MISC FEATURE
      (1)...(43)
<222>
<223> Only a contiguous fragment of residues 1-43 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<400> 20
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                25
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Ile Ser Gln Ala Val
                            40
His Ala Ala His Ala Glu Ile Asn Glu Ala Gly Arg
                        55
<210>
       21
<211> 142
<212> PRT
<213> Artificial
<220>
<223> Fusion protein
<220>
<221> MISC_FEATURE
<222> (14)..(56)
<223> Only a contiguous fragment of residues 14-56 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221> MISC FEATURE
<222> (57)..(99)
```

<223> Only a contiguous fragment of residues 57-99 are present.

Preferred fragments are 5-10 or 7-10 residues in length.

<220>

- <221> MISC FEATURE
- <222> (100)..(142)
- <223> Only a contiguous fragment of residues 100-142 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<400> 21

Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Asp Ala Glu 1 10 15

Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe 20 25 30

Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met  $35 \hspace{1.5cm} 40 \hspace{1.5cm} 45$ 

Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser 50 55 60

Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val 65 70 75 80

Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val 85 90 95

Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His  $100 \hspace{1.5cm} 105 \hspace{1.5cm} 110 \hspace{1.5cm}$ 

His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly 115 120 125

Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr 130 135 140

<210> 22

<211> 99

<212> PRT

<213> Artificial

<220>

<223> Fusion protein

<220>

- <221> MISC\_FEATURE
- <222> (1)..(43)
- <223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.

```
<220>
<221>
      MISC FEATURE
<222>
      (57)..(99)
      Only a contiguous fragment of residues 57-99 are present.
<223>
       Preferred fragments are 5-10 or 7-10 residues in length.
<400> 22
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
                                    10
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                25
Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Pro Lys Tyr Val Lys
                                                45
        35
                            40
Gln Asn Thr Leu Lys Leu Ala Thr Asp Ala Glu Phe Arg His Asp Ser
    50
                        55
Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val
                    70
Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val
                85
Ile Ala Thr
<210>
      23
<211> 142
<212> PRT
<213> Artificial
<220>
<223> Fusion protein
<220>
<221>
      MISC FEATURE
<222>
      (1)..(43)
       Only a contiguous fragment of residues 1-43 are present.
<223>
       Preferred fragments are 5-10 or 7-10 residues in length.
<220>
<221>
      MISC FEATURE
<222>
      (44)..(86)
<223> Only a contiguous fragment of residues 44-86 are present.
       Preferred fragments are 5-10 or 7-10 residues in length.
```

<220>

<221> MISC FEATURE

```
<222> (87)..(129)
```

<223> Only a contiguous fragment of residues 87-129 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<400> 23

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg  $35 \hspace{1cm} 40 \hspace{1cm} 45$ 

His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala 50 55 60

Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly 65 70 75 80

Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly. Tyr 85 90 95

Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser 100 105 110

Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala 115 120 125

Thr Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr 130 135 140

<210> 24

<211> 99

<212> PRT

<213> Artificial

<220>

<223> Fusion protein

<220>

<221> MISC\_FEATURE

<222> (1)..(43)

<223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (44)..(86)

<223> Only a contiguous fragment of residues 44-86 are present.

Preferred fragments are 5-10 or 7-10 residues in length.

<400> 24

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg 35 40 45

His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala 50 55 60

Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly 65 70 75 80

Gly Val Val Ile Ala Thr Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys 85 90 95

Leu Ala Thr

<210> 25

<211> 316

<212> PRT

<213> Artificial

<220>

<223> Fusion protein

<220>

<221> MISC FEATURE

<222> (1)..(43)

<223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (109)..(151)

<223> Only a contiguous fragment of residues 109-151 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (152)..(194)

<223> Only a contiguous fragment of residues 152-194 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC\_FEATURE

- <222> (195)..(237)
- <223> Only a contiguous fragment of residues 195-237 are present. Preferred fragments are 5-10 or 7-10 residues in length.
- <220>
- <221> MISC FEATURE
- <222> (238)..(280)
- <223> Only a contiguous fragment of residues 238-280 are present. Preferred fragments are 5-10 or 7-10 residues in length.
- <400> 25
- Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 10 15
- Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30
- Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Pro Lys Tyr Val Lys  $35 \hspace{1cm} 40 \hspace{1cm} 45$
- Gln Asn Thr Leu Lys Leu Ala Thr Glu Lys Lys Ile Ala Lys Met Glu 50 55 60
- Lys Ala Ser Ser Val Phe Asn Val Gln Tyr Ile Lys Ala Asn Ser Lys 65 70 75 80
- Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp 85 90 95
- Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Asp Ala Glu Phe 100 105 110
- Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe 115 120 125
- Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val 130 135 140
- Gly Gly Val Val Ile Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly 145 150 155 160
- Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly 165 170 175
- Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile 180 185 190
- Ala Thr Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His

195 200 205

Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala 210 215 220

Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Asp Ala Glu 225 230 235 240

Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe 245 250 255

Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met 260 265 270

Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala Asn Ser Lys 275 280 285

Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp 290 295 300

Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 305 310 315

<210> 26

<211> 203

<212> PRT

<213> Artificial

<220>

<223> Fusion protein

<220>

<221> MISC FEATURE

<222> (1)..(43)

<223> Only a contiguous fragment of residues 1-43 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (81)..(123)

<223> Only a contiguous fragment of residues 81-123 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<220>

<221> MISC FEATURE

<222> (161)..(203)

<223> Only a contiguous fragment of residues 161-203 are present. Preferred fragments are 5-10 or 7-10 residues in length.

<400> 26

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala 35 40 45

Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr 50 55 60

Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 65 70 75 80

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 85 90 95

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 100 105 110

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala 115 120 125

Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr 130 135 140

Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 145 150 155 160

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 165 170 175

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 180 185 190

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr 195 200

<210> 27

<211> 58

<212> PRT

<213> Artificial

<220>

<223> Fusion protein

<220>

- <221> MISC FEATURE
- <222> (1)..(43)
- <223> Only a contiguous fragment of residues 1-43are present. Preferred fragments are 5-10 or 7-10 residues in length.

<400> 27

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala 35 40 45

Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 50 55